Connection

Co-Authors

This is a "connection" page, showing publications co-authored by MARK J ROUTBORT and ALEXANDER LAZAR.
Connection Strength

0.686
  1. How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments? J Natl Compr Canc Netw. 2016 06; 14(6):787-92.
    View in: PubMed
    Score: 0.139
  2. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2644-51.
    View in: PubMed
    Score: 0.127
  3. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Arch Pathol Lab Med. 2021 11 01; 145(11):1405-1412.
    View in: PubMed
    Score: 0.051
  4. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol. 2021 05; 129(5):374-382.
    View in: PubMed
    Score: 0.047
  5. Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays. Arch Pathol Lab Med. 2019 04; 143(4):463-471.
    View in: PubMed
    Score: 0.041
  6. Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.040
  7. Challenges in next generation sequencing analysis of somatic mutations in transplant patients. Cancer Genet. 2018 10; 226-227:17-22.
    View in: PubMed
    Score: 0.040
  8. A Window Into Clinical Next-Generation Sequencing-Based Oncology Testing Practices. Arch Pathol Lab Med. 2017 Dec; 141(12):1679-1685.
    View in: PubMed
    Score: 0.038
  9. Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.
    View in: PubMed
    Score: 0.036
  10. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21.
    View in: PubMed
    Score: 0.033
  11. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
    View in: PubMed
    Score: 0.032
  12. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015 May; 42(5):308-17.
    View in: PubMed
    Score: 0.032
  13. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.